Clear Harbor Asset Management LLC Cuts Stock Holdings in uniQure (NASDAQ:QURE)

Clear Harbor Asset Management LLC decreased its position in uniQure (NASDAQ:QURE) by 12.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 17,000 shares of the biotechnology company’s stock after selling 2,500 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in uniQure were worth $300,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. American Century Companies Inc. grew its position in uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 8,642 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares during the last quarter. Marshall Wace LLP bought a new position in shares of uniQure in the second quarter valued at approximately $175,000. Cubist Systematic Strategies LLC increased its position in shares of uniQure by 130.9% during the second quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 14,454 shares during the last quarter. Finally, Algert Global LLC bought a new stake in uniQure during the second quarter worth $176,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.74% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on QURE shares. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. The Goldman Sachs Group lifted their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Stifel Nicolaus increased their target price on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Finally, Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.38.

uniQure Price Performance

Shares of NASDAQ QURE opened at $15.29 on Thursday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The stock has a market cap of $745.23 million, a PE ratio of -3.08 and a beta of 0.41. The stock has a fifty day moving average of $12.39 and a 200-day moving average of $8.56.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. Equities research analysts anticipate that uniQure will post -3.74 earnings per share for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.